PSA Standardization
Development of PSA Standards
October 2009
However, in 1995, Stamey and colleagues published an article showing that the extinction coefficient for PSA was actually 1.84 mL/mg/cm, and they determined this using quantitative amino acid analysis. The previous extinction coefficient used for PSA standards with the Hybritech assay was 1.42 mL/mg/cm, approximately a 23% difference, with the Hybritech concentration reading higher than the more accurately determined standard. At that time Stamey hypothesized this finding would lead to the Hybritech Tandem-R assay reading 10-20% “too high.” In 1999, the World Health Organization (WHO) established the First International Reference Preparation for PSA (WHO standards 96/670 for total and 96/668 for free PSA). This standard is a recombinant DNA-derived human PSA, which was standardized using the new extinction coefficient.
Although many of the commercial PSA methods used at that time yielded values that were higher than the WHO-assigned value, very little attention came from the medical community about the potential impact of this new standard on prostate cancer screening. Manufacturers then began to standardize PSA assays to the WHO standard, as recommended. Finally, in 2003 it was noted that the change or differences between the Hybritech and WHO standards may have an effect on the medical decision levels.
Development of PSA Standards |
Jump to section:
- Introduction
- Elevated PSA Result on Screening
- Reasons for Ordering PSA1
- PSA Screening in the News
- Recommendations for Screening
- Arguments for Screening for Prostate Cancer
- Recommendations for Not Screening
- Arguments Against Screening for Prostate Cancer
- PSA Sensitivity and Specificity
- High-Grade Prostate Cancer is Not Rare When PSA =4.0 ng/mL6
- Increase Specificity Using PSA Velocity8
- Optimizing Clinical Sensitivity and Specificity: Age/Ethnic Reference Intervals9,10
- Utilization of Free/Total PSA Ratio11
- Why Aren't PSA Results Interchangeable?
- Development of PSA Standards
- Development of PSA Standards
- Effect of Analytical Bias on Classification Based on Fixed Criteria
- Analytical Difference: Results per 1000 Patients Tested13
- Hybritech vs. WHO Standardized Assays12,14
- Analytical Differences15
- CAP Proficiency Testing
- WHO 96/670 Total PSA Preparations16
- WHO Calibration/Concordance at 3.1 ng/mL Cutoff5
- WHO Calibration/Concordance at 3.1 ng/mL Cutoff5
- WHO Calibration/Concordance at 4.0 ng/mL Cutoff5
- Clinical Differences in PSA Screening14
- The Clinical Difference
- Fixed Thresholds Produce Problems for Biopsy Recommendations
- Effect on "Watchful Waiting"
- Effect on "Watchful Waiting"
- Adding Biological Variability into the Mix
- Futures in Prostate Cancer Testing?
- PSA Testing at Mayo
- Conclusions
- References
- References
- Questions?


